SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Trial Start • Phase 1Trial initiation Tue, Jun 30, 2026, 8:00 AM EDT
Company profile
Scynexis, Inc.
Pipeline4 assets
- SCY-770PXL-770 / AMP-activated protein kinase (AMPK) / Small Molecule / Rare Diseases / NephrologyAutosomal Dominant Polycystic Kidney Disease (ADPKD)Phase 2ActiveGlobal
- SCY-247SCY-247 / 1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesTreatment and Prevention of Invasive Fungal InfectionsPhase 1ActiveUnited States
- Fungerp analogs1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesTreatment of resistant fungiPreclinicalActiveGlobal
- IbrexafungerpSCY-078 / BREXAFEMME / 1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesVulvovaginal candidiasis (VVC) and Recurrent VVCApprovedActiveUnited StatesInvasive Candidiasis (IC)Phase 3ActiveGlobal
Latest news10 items
All newsSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
Trial Start • Phase 1
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Trial Start • Phase 1